Agenix antibody in US diagnostic test
Thursday, 17 February, 2005
AGEN Biomedical, a subsidiary of Brisbane-based biotech Agenix (ASX: AGX), is set to receive royalties from a newly launched test developed by US diagnostics company Biosite that uses AGEN's D-Dimer antibody.
Biosite's Triage D-Dimer diagnostic is a point-of-care diagnostic for the assessment and evaluation of patients suspected of having thromboembolic events including pulmonary embolism and deep vein thrombosis. The ELISA-based test measures five biomarkers including D-Dimer, and provides results within 15 minutes. AGEN licensed the D-Dimer antibody and associated IP to Biosite in November 2003.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
